Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Phathom Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Phathom Pharmaceuticals, Inc.’s stock price such as:

• Phathom Pharmaceuticals, Inc.’s current stock price and volume
• Why Phathom Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for PHAT from analysts
• PHAT’s stock price momentum as measured by its relative strength

About Phathom Pharmaceuticals, Inc. (PHAT)

Before we jump into Phathom Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Want to learn more about Phathom Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Phathom Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of June 18, 2026, 4:00 PM, CST, Phathom Pharmaceuticals, Inc.’s stock price was $10.880.

Phathom Pharmaceuticals, Inc. is 0% from its previous closing price of $10.880.

During the last market session, Phathom Pharmaceuticals, Inc.’s stock traded between $10.590 and $11.400. Currently, there are approximately 82.05 million shares outstanding for Phathom Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Phathom Pharmaceuticals, Inc. Stock Price History

Phathom Pharmaceuticals, Inc.’s (PHAT) price is currently up 13.45% so far this month.

During the month of June, Phathom Pharmaceuticals, Inc.’s stock price has reached a high of $11.400 and a low of $8.780.

Over the last year, Phathom Pharmaceuticals, Inc. has hit prices as high as $18.310 and as low as $7.610. Year to date, Phathom Pharmaceuticals, Inc.’s stock is down 34.42%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Phathom Pharmaceuticals, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 18, 2026, there was 1 analyst who downgraded Phathom Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Phathom Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Phathom Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Phathom Pharmaceuticals, Inc. (PHAT) by visiting AAII Stock Evaluator.

Relative Price Strength of Phathom Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 18, 2026, Phathom Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -6.02%, which translates to a Momentum Score of 39 and is considered to be Weak.

Want to learn more about how Phathom Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Phathom Pharmaceuticals, Inc. Stock Price: Bottom Line

As of June 18, 2026, Phathom Pharmaceuticals, Inc.’s stock price is $10.880, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Phathom Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.